BioVie announces poster on patient-centric accessibility of SUNRISE-PD trial

BioVie (BIVI) announced that a poster highlighting the patient-centric design and accessibility of its ongoing SUNRISE-PD Phase 2 clinical trial will be presented at the Advanced Therapeutics in Movement & Related Disorders Congress, to be held at National Harbor, MD, from June 27-30, 2025. People with Parkinson’s disease often face barriers to accessing specialized care and participating in clinical trials due to delayed diagnosis, limited mobility, and geographic constraints. SUNRISE-PD is a Phase 2 trial evaluating bezisterim in individuals with early-stage PD that aims to address these challenges through a hybrid, decentralized design. “SUNRISE-PD represents the future of clinical trial design one that meets people where they are and makes participation possible without compromising scientific rigor,” said Cuong Do, President and CEO of BioVie Inc. “By combining an innovative therapeutic approach with a decentralized model, we are exploring the potential of bezisterim to impact the course of Parkinson’s disease and set a precedent for how studies can be more inclusive, accessible and patient-focused.”